Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAO1 | P09471 | 5/20 | 0.45 |
| ▸ | GNAI3 | P08754 | 4/20 | 0.45 |
| ▸ | GNAI1 | P63096 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 3/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1795218 | 0.98 | GNAO1 (0.47) | GNAO1GNAI3GNAI1SMN1; SMN2ALDH1A1 | |
| SCHEMBL4059891 | 0.89 | GNAO1 (0.54) | GNAO1GNAI3GNAI1SIGMAR1 | |
| SCHEMBL639712 | 0.89 | HTR6 (0.43) | GNAO1GNAI3GNAI1SMN1; SMN2ALDH1A1 | |
| SCHEMBL639711 | 0.89 | HTR6 (0.43) | GNAO1GNAI3GNAI1SMN1; SMN2ALDH1A1 | |
| SCHEMBL25955424 | 0.87 | GNAO1 (0.61) | GNAO1GNAI3GNAI1 | |
| SCHEMBL23135123 | 0.86 | SMN1; SMN2 (0.45) | SMN1; SMN2ALDH1A1DRD2SIGMAR1KMT2A | |
| SCHEMBL6280566 | 0.85 | SMN1; SMN2 (0.46) | GNAO1GNAI3GNAI1SMN1; SMN2ALDH1A1 | |
| SCHEMBL1479533 | 0.84 | KMT2A (0.42) | GNAO1GNAI3GNAI1SMN1; SMN2KMT2A | |
| Hydrochloric Acid SCHEMBL15352805 | 0.82 | KMT2A (0.41) | GNAO1GNAI3GNAI1SMN1; SMN2KMT2A | |
| SCHEMBL27349923 | 0.82 | CXCR4 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023066363-A1 | PARP-1 DEGRADATION AGENT AND USE THEREOF | 海思科医药集团股份有限公司 | 2023-04-27 | — | — | WO | disclosed |
| EP-3630744-B1 | PYRAZOLE MAGL INHIBITORS | H LUNDBECK AS (DK) | 2023-01-25 | — | — | EP | disclosed |
| US-9403796-B2 | Amidomethyl-substituted oxindole derivatives and the use thereof for the treatment of vasopressin-dependent illnesses | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-08-02 | — | — | US | disclosed |
| US-20140275110-A1 | AMIDOMETHYL-SUBSTITUTED OXINDOLE DERIVATIVES AND THE USE THEREOF FOR THE TREATMENT OF VASOPRESSIN-DEPENDENT ILLNESSES | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-09-18 | — | — | US | disclosed |
| US-8703775-B2 | Amidomethyl-substituted oxindole derivatives and the use thereof for the treatment of vasopressin-dependent illnesses | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-04-22 | — | — | US | disclosed |
| US-20110077253-A1 | AMIDOMETHYL-SUBSTITUTED OXINDOLE DERIVATIVES AND THE USE THEREOF FOR THE TREATMENT OF VASOPRESSIN-DEPENDENT ILLNESSES | ABBOTT GMBH & CO. KG (DE) | 2011-03-31 | — | — | US | disclosed |
| EP-1606288-A1 | BENZENESULPHONAMIDE DERIVATIVES, METHOD FOR PRODUCTION AND USE THEREOF FOR TREATMENT OF PAIN | LABORATOIRES FOURNIER S.A. (FR) | 2005-12-21 | — | — | EP | disclosed |
| WO-2004087700-A1 | BENZENESULPHONAMIDE DERIVATIVES, METHOD FOR PRODUCTION AND USE THEREOF FOR TREATMENT OF PAIN | LABORATOIRES FOURNIER S.A. (FR) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077253-A1 | AMIDOMETHYL-SUBSTITUTED OXINDOLE DERIVATIVES AND THE USE THEREOF FOR THE TREATMENT OF VASOPRESSIN-DEPENDENT ILLNESSES | AVPR2, AVPR1B, AVPR1A | GNAO1 640/4885GNAI3 281/4885GNAI1 475/4885 |
| US-20140275110-A1 | AMIDOMETHYL-SUBSTITUTED OXINDOLE DERIVATIVES AND THE USE THEREOF FOR THE TREATMENT OF VASOPRESSIN-DEPENDENT ILLNESSES | AVPR2, AVPR1B, AVPR1A | GNAO1 640/4885GNAI3 281/4885GNAI1 475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.